GCIA
DMIIU

Gabelli & Co Investment Advisers’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-179,500
Closed -$1.8M – 350
2025
Q4 		$1.8M Buy
179,500
+23,700
+15% +$237K 0.27% 78
2025
Q3 		$1.55M Buy
+155,800
New +$1.55M 0.25% 83

Other funds holding DMIIU

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
LGM
L1 Global Manager Melbourne $142M AUM
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Gabelli & Co Investment Advisers's DMIIU Position: Q1 2026 in Review

Gabelli & Co Investment Advisers sold out of Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q1 2026, closing a stake of 179,500 shares — an estimated $1.8M sold.

Gabelli & Co Investment Advisers first reported a position in DMIIU in Q3 2025 and held it in 2 quarters. The position peaked at $1.8M in Q4 2025. 14 funds tracked by Wall St. Rank hold DMIIU as of Q1 2026.

  • Gabelli & Co Investment Advisers reported no remaining Drugs Made In America Acquisition II Corp Unit position as of Q1 2026 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 179,500 Drugs Made In America Acquisition II Corp Unit shares in Q1 2026, an estimated $1.8M.
  • Gabelli & Co Investment Advisers first reported a position in Drugs Made In America Acquisition II Corp Unit in Q3 2025 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Drugs Made In America Acquisition II Corp Unit position peaked at $1.8M in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.